Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action - PubMed (original) (raw)

Review

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

Alok A Khorana et al. J Clin Oncol. 2009.

Abstract

Purpose: Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its treatments, and is associated with worsened mortality and morbidity in patients with cancer.

Design: The Italian Association of Medical Oncology, the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the French National Federation of the League of Centers Against Cancer, and the European Society of Medical Oncology have recently published guidelines regarding VTE in patients with cancer. This review, authored by a working group of members from these panels, focuses on the methodology and areas of consensus and disagreement in the various clinical guidelines as well as directions for future research.

Results: There is broad consensus regarding the importance of thromboprophylaxis in hospitalized patients with cancer, including prolonged prophylaxis in high-risk surgical patients. Prophylaxis is not currently recommended for ambulatory patients with cancer (with exceptions) or for central venous catheters. All of the panels agree that low molecular weight heparins are preferred for the long-term treatment of VTE in cancer. Areas that warrant further research include the benefit of prophylaxis in the ambulatory setting, the risk/benefit ratio of prophylaxis for hospitalized patients with cancer, an understanding of incidental VTE, and the impact of anticoagulation on survival.

Conclusion: We call for a sustained research effort to investigate the clinical issues identified here to reduce the burden of VTE and its consequences in patients with cancer.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Cited by

Thromboprophylaxis in patients receiving inpatient palliative care: a survey of present practice in Austria.
Gartner V, Kierner KA, Namjesky A, Kum-Taucher B, Hammerl-Ferrari B, Watzke HH, Stabel C; AUPACS group. Gartner V, et al. Support Care Cancer. 2012 Sep;20(9):2183-7. doi: 10.1007/s00520-011-1330-6. Epub 2011 Nov 26. Support Care Cancer. 2012. PMID: 22119936
Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day.
Gardiner C, Harrison P, Belting M, Böing A, Campello E, Carter BS, Collier ME, Coumans F, Ettelaie C, van Es N, Hochberg FH, Mackman N, Rennert RC, Thaler J, Rak J, Nieuwland R. Gardiner C, et al. J Extracell Vesicles. 2015 Mar 13;4:26901. doi: 10.3402/jev.v4.26901. eCollection 2015. J Extracell Vesicles. 2015. PMID: 25773446 Free PMC article.
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.
Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, Clemons M. Jacobs C, et al. PLoS One. 2014 Oct 17;9(10):e110469. doi: 10.1371/journal.pone.0110469. eCollection 2014. PLoS One. 2014. PMID: 25329669 Free PMC article.
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. Sonpavde G, et al. Curr Oncol Rep. 2012 Aug;14(4):295-306. doi: 10.1007/s11912-012-0237-9. Curr Oncol Rep. 2012. PMID: 22532265 Review.
A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.
Smith JD, Baillie J, Baglin T, Griffiths GO, Casbard A, Cohen D, Fitzmaurice DA, Hood K, Rose P, Cohen AT, Johnson M, Maraveyas A, Bell J, Toone H, Nelson A, Noble SI. Smith JD, et al. Trials. 2014 Apr 12;15:122. doi: 10.1186/1745-6215-15-122. Trials. 2014. PMID: 24726032 Free PMC article. Clinical Trial.

References

1. Khorana AA. Malignancy, thrombosis and Trousseau: The case for an eponym. J Thromb Haemost. 2003;1:2463–2465. - PubMed
1. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest. 2009;27:105–115. - PubMed
1. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–2346. - PubMed
1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634. - PubMed
1. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850. - PubMed

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action - PubMed (original) (raw)